Validating neuro-QoL short forms and targeted scales with people who have multiple sclerosis

Deborah M. Miller*, Francois Bethoux, David Victorson, Cindy J. Nowinski, Sarah Buono, Jin Shei Lai, Katy Wortman, James L. Burns, Claudia Moy, David Cella

*Corresponding author for this work

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses. Objective: The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS. Methods: We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients. Results: Internal consistency was high for all measures (a = 0.81-0.95) and ICCs were within the acceptable range (0.76-0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group. Conclusions: The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.

Original languageEnglish (US)
Pages (from-to)830-841
Number of pages12
JournalMultiple Sclerosis
Volume22
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Multiple Sclerosis
Quality of Life
Neurology
Central Nervous System Diseases
Reproducibility of Results
Disease Progression
Clinical Trials
Research
Population

Keywords

  • Health-related quality of life
  • Multiple sclerosis
  • Neuro-QOL
  • Patient-reported outcomes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Miller, Deborah M. ; Bethoux, Francois ; Victorson, David ; Nowinski, Cindy J. ; Buono, Sarah ; Lai, Jin Shei ; Wortman, Katy ; Burns, James L. ; Moy, Claudia ; Cella, David. / Validating neuro-QoL short forms and targeted scales with people who have multiple sclerosis. In: Multiple Sclerosis. 2015 ; Vol. 22, No. 6. pp. 830-841.
@article{152de178aec0415b870c6b1e528c57c4,
title = "Validating neuro-QoL short forms and targeted scales with people who have multiple sclerosis",
abstract = "Background: Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses. Objective: The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS. Methods: We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients. Results: Internal consistency was high for all measures (a = 0.81-0.95) and ICCs were within the acceptable range (0.76-0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group. Conclusions: The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.",
keywords = "Health-related quality of life, Multiple sclerosis, Neuro-QOL, Patient-reported outcomes",
author = "Miller, {Deborah M.} and Francois Bethoux and David Victorson and Nowinski, {Cindy J.} and Sarah Buono and Lai, {Jin Shei} and Katy Wortman and Burns, {James L.} and Claudia Moy and David Cella",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/1352458515599450",
language = "English (US)",
volume = "22",
pages = "830--841",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

Validating neuro-QoL short forms and targeted scales with people who have multiple sclerosis. / Miller, Deborah M.; Bethoux, Francois; Victorson, David; Nowinski, Cindy J.; Buono, Sarah; Lai, Jin Shei; Wortman, Katy; Burns, James L.; Moy, Claudia; Cella, David.

In: Multiple Sclerosis, Vol. 22, No. 6, 01.01.2015, p. 830-841.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Validating neuro-QoL short forms and targeted scales with people who have multiple sclerosis

AU - Miller, Deborah M.

AU - Bethoux, Francois

AU - Victorson, David

AU - Nowinski, Cindy J.

AU - Buono, Sarah

AU - Lai, Jin Shei

AU - Wortman, Katy

AU - Burns, James L.

AU - Moy, Claudia

AU - Cella, David

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses. Objective: The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS. Methods: We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients. Results: Internal consistency was high for all measures (a = 0.81-0.95) and ICCs were within the acceptable range (0.76-0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group. Conclusions: The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.

AB - Background: Multiple sclerosis (MS) is a chronic, progressive, and disabling disease of the central nervous system with dramatic variations in the combination and severity of symptoms it can produce. The lack of reliable disease-specific health-related quality of life (HRQL) measures for use in clinical trials prompted the development of the Neurology Quality of Life (Neuro-QOL) instrument, which includes 13 scales that assess physical, emotional, cognitive, and social domains, for use in a variety of neurological illnesses. Objective: The objective of this research paper is to conduct an initial assessment of the reliability and validation of the Neuro-QOL short forms (SFs) in MS. Methods: We assessed reliability, concurrent validity, known groups validity, and responsiveness between cross-sectional and longitudinal data in 161 recruited MS patients. Results: Internal consistency was high for all measures (a = 0.81-0.95) and ICCs were within the acceptable range (0.76-0.91); concurrent and known groups validity were highest with the Global HRQL question. Longitudinal assessment was limited by the lack of disease progression in the group. Conclusions: The Neuro-QOL SFs demonstrate good internal consistency, test-re-test reliability, and concurrent and known groups validity in this MS population, supporting the validity of Neuro-QOL in adults with MS.

KW - Health-related quality of life

KW - Multiple sclerosis

KW - Neuro-QOL

KW - Patient-reported outcomes

UR - http://www.scopus.com/inward/record.url?scp=85016184031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016184031&partnerID=8YFLogxK

U2 - 10.1177/1352458515599450

DO - 10.1177/1352458515599450

M3 - Article

C2 - 26238464

AN - SCOPUS:85016184031

VL - 22

SP - 830

EP - 841

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 6

ER -